Dr.Reddy's Laboratories Ltd (REDY.BO)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|50||2014||Chairman of the Board|
|57||2014||Co-Chairman of the Board, Chief Executive Officer, Managing Director|
|56||2012||President, Chief Financial Officer, Global Head - HR and IT & BPE|
|60||2013||President, Global Head - Human Resources|
|49||2018||Chief Operating Officer and Global Head of Generics & PSAI|
- Indivior plans cheaper opioid addiction drug if rivals launch copycats
- UPDATE 2-Cost cuts help drugmaker Indivior as it battles cheap rival
- UPDATE 1-Indian drugmaker Dr. Reddy's Q2 profit soars past market estimates
- Indivior: U.S. court rules against generic rival's appeal
- UPDATE 1-Indivior: U.S. court rules against generic rival's appeal